Literature DB >> 22684241

A statistical approach to central monitoring of data quality in clinical trials.

David Venet1, Erik Doffagne, Tomasz Burzykowski, François Beckers, Yves Tellier, Eric Genevois-Marlin, Ursula Becker, Valerie Bee, Veronique Wilson, Catherine Legrand, Marc Buyse.   

Abstract

BACKGROUND: Classical monitoring approaches rely on extensive on-site visits and source data verification. These activities are associated with high cost and a limited contribution to data quality. Central statistical monitoring is of particular interest to address these shortcomings.
PURPOSE: This article outlines the principles of central statistical monitoring and the challenges of implementing it in actual trials.
METHODS: A statistical approach to central monitoring is based on a large number of statistical tests performed on all variables collected in the database, in order to identify centers that differ from the others. The tests generate a high-dimensional matrix of p-values, which can be analyzed by statistical methods and bioinformatic tools to identify extreme centers.
RESULTS: Results from actual trials are provided to illustrate typical findings that can be expected from a central statistical monitoring approach, which detects abnormal patterns that were not (or could not have been) detected by on-site monitoring. LIMITATIONS: Central statistical monitoring can only address problems present in the data. Important aspects of trial conduct such as a lack of informed consent documentation, for instance, require other approaches. The results provided here are empirical examples from a limited number of studies.
CONCLUSION: Central statistical monitoring can both optimize on-site monitoring and improve data quality and as such provides a cost-effective way of meeting regulatory requirements for clinical trials.

Mesh:

Year:  2012        PMID: 22684241     DOI: 10.1177/1740774512447898

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  26 in total

Review 1.  Data-driven risk identification in phase III clinical trials using central statistical monitoring.

Authors:  Catherine Timmermans; David Venet; Tomasz Burzykowski
Journal:  Int J Clin Oncol       Date:  2015-08-02       Impact factor: 3.402

2.  Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial.

Authors:  Catherine Timmermans; Erik Doffagne; David Venet; Lieven Desmet; Catherine Legrand; Tomasz Burzykowski; Marc Buyse
Journal:  Gastric Cancer       Date:  2015-08-23       Impact factor: 7.370

Review 3.  Statistical challenges for central monitoring in clinical trials: a review.

Authors:  Koji Oba
Journal:  Int J Clin Oncol       Date:  2015-10-23       Impact factor: 3.402

Review 4.  The impact of clinical trial monitoring approaches on data integrity and cost--a review of current literature.

Authors:  Rasmus Olsen; Asger Reinstrup Bihlet; Faidra Kalakou; Jeppe Ragnar Andersen
Journal:  Eur J Clin Pharmacol       Date:  2016-01-04       Impact factor: 2.953

5.  Data fraud in clinical trials.

Authors:  Stephen L George; Marc Buyse
Journal:  Clin Investig (Lond)       Date:  2015

Review 6.  Strategies for dealing with fraud in clinical trials.

Authors:  Jay Herson
Journal:  Int J Clin Oncol       Date:  2015-07-21       Impact factor: 3.402

Review 7.  Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations.

Authors:  Jennifer S Gewandter; Robert H Dworkin; Dennis C Turk; Eric G Devine; David Hewitt; Mark P Jensen; Nathaniel P Katz; Amy A Kirkwood; Richard Malamut; John D Markman; Bernard Vrijens; Laurie Burke; James N Campbell; Daniel B Carr; Philip G Conaghan; Penney Cowan; Mittie K Doyle; Robert R Edwards; Scott R Evans; John T Farrar; Roy Freeman; Ian Gilron; Dean Juge; Robert D Kerns; Ernest A Kopecky; Michael P McDermott; Gwendolyn Niebler; Kushang V Patel; Richard Rauck; Andrew S C Rice; Michael Rowbotham; Nelson E Sessler; Lee S Simon; Neil Singla; Vladimir Skljarevski; Tina Tockarshewsky; Geertrui F Vanhove; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2019-12-13       Impact factor: 5.820

8.  Truths, lies, and statistics.

Authors:  Matthew S Thiese; Skyler Walker; Jenna Lindsey
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

9.  A randomized evaluation of on-site monitoring nested in a multinational randomized trial.

Authors:  Nicole Wyman Engen; Kathy Huppler Hullsiek; Waldo H Belloso; Elizabeth Finley; Fleur Hudson; Eileen Denning; Catherine Carey; Mary Pearson; Jonathan Kagan
Journal:  Clin Trials       Date:  2019-10-24       Impact factor: 2.486

10.  Closeout of the HALT-PKD trials.

Authors:  Charity G Moore; Susan Spillane; Gertrude Simon; Barbara Maxwell; Frederic F Rahbari-Oskoui; William E Braun; Arlene B Chapman; Robert W Schrier; Vicente E Torres; Ronald D Perrone; Theodore I Steinman; Godela Brosnahan; Peter G Czarnecki; Peter C Harris; Dana C Miskulin; Michael F Flessner; K Ty Bae; Kaleab Z Abebe; Marie C Hogan
Journal:  Contemp Clin Trials       Date:  2015-07-29       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.